SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended September 30, 2011. Key financial results include:
•Total revenues of $26.8 million increased 48% over the prior year period •Net income of $0.6 million, or $0.01 per diluted share, compared with a net loss of $25.7 million, or $0.44 per share, for the 2010 third quarter, which included one-time restructuring costs of $7.3 million and a $15 million upfront payment to acquire rights to RHUCIN®
